RET and thyroid gland carcinoma: It has been also shown that CLM3 and CLM29 (another pyrazolo[3,4-d]pyrimidine, inhibiting RET, EGFR, and VEGFR, with antiangiogenic activity) (82) inhibited the migration of papillary dedifferentiated thyroid cancer (DePTC) cells.